Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

Table 1

Baseline characteristics of the patients in the per-protocol population (n = 54).

Table 1

doi: https://doi.org/10.1371/journal.pone.0215135.t001